Literature DB >> 25656693

Systematic review and meta-analysis of the spectrum and outcomes of different histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms.

Ye Xin Koh1, Hui Li Zheng2, Aik-Yong Chok1, Chuen Seng Tan2, Wyiki Wyone1, Tony K H Lim3, Damien M Y Tan4, Brian K P Goh5.   

Abstract

BACKGROUND: Our aim was to review the available evidence to determine the clinical importance of the histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms (IPMNs) on disease characteristics and overall survival.
METHODS: We reviewed systematically 14 comparative studies that reported clinicopathologic characteristics and survival of 1,617 patients with IPMN (900 noninvasive and 717 invasive).
RESULTS: The pancreatobiliary subtype was associated with the greatest likelihood of tumor invasion (67.9%; odds ratio [OR], 2.87; 95% CI, 1.90-4.35), harboring an associated mural nodule (56.6%; OR, 2.92; 95% CI, 1.21-7.04), demonstrating tumor recurrence (46.3%; OR, 3.28; 95% CI, 1.41-7.66) and transformation to tubular adenocarcinoma (81.8%; OR, 92.96; 95% CI, 20.76-416.28) among all subtypes. The gastric subtype was associated with the least likelihood of tumor invasion (10.2%; OR, 0.18; 95% CI, 0.13-0.26), association with main duct IPMN (19.2%; OR, 0.12; 95% CI, 0.06-0.26), and tumor recurrence (9.4%; OR, 0.47; 95% CI, 0.26-0.83) among all subtypes. The intestinal subtype had the greatest likelihood of progressing to colloid carcinoma among all subtypes. Tubular adenocarcinoma was associated with an increased risk of vascular invasion (32.9%; OR, 4.86; 95% CI, 1.96-12.01), perineural invasion (54.5%; OR, 2.30; 95% CI, 1.22-4.34), nodal metastasis (52.4%; OR, 3.31; 95% CI, 1.79-6.14), and a positive margin status (17.3%; OR, 8.45; 95% CI, 1.52-46.83). Tubular adenocarcinoma (hazard ratio [HR], 1.90; 95% CI, 1.36-2.67) had a poorer 5-year overall survival compared with colloid carcinoma and was similar to the survival observed in pancreatic ductal adenocarcinoma (HR, 2.00; 95% CI, 1.59-2.52).
CONCLUSION: The prognosis of IPMN depends on its pathologic subtype. Subtype identification should be considered an essential component in future guidelines for the management of IPMN.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25656693     DOI: 10.1016/j.surg.2014.08.098

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  16 in total

Review 1.  Natural History of Pancreatic Cysts.

Authors:  Alexander Larson; Richard S Kwon
Journal:  Dig Dis Sci       Date:  2017-03-17       Impact factor: 3.199

2.  Imaging of pancreatic cystic lesions with confocal laser endomicroscopy: an ex vivo pilot study.

Authors:  Abdurrahman Kadayifci; Mustafa Atar; Michelle Yang; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; William R Brugge
Journal:  Surg Endosc       Date:  2017-04-25       Impact factor: 4.584

Review 3.  [Resection of main duct and mixed type IPMN ≥5 mm].

Authors:  G O Ceyhan; F Scheufele; H Friess
Journal:  Chirurg       Date:  2017-11       Impact factor: 0.955

4.  International guidelines for the management of pancreatic intraductal papillary mucinous neoplasms.

Authors:  Brian K P Goh
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

5.  Prognosis of resected intraductal papillary mucinous neoplasm of the pancreas: using revised 2017 international consensus guidelines.

Authors:  Ji Hye Min; Young Kon Kim; Honsoul Kim; Dong Lk Cha; Soohyun Ahn
Journal:  Abdom Radiol (NY)       Date:  2020-06-24

6.  Interobserver variability in intraductal papillary mucinous neoplasm subtypes and application of their mucin immunoprofiles.

Authors:  Heewon A Kwak; Xiuli Liu; Daniela S Allende; Rish K Pai; John Hart; Shu-Yuan Xiao
Journal:  Mod Pathol       Date:  2016-05-20       Impact factor: 7.842

Review 7.  Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base.

Authors:  W Cory Johnston; Helena M Hoen; Maria A Cassera; Pippa H Newell; Chet W Hammill; Paul D Hansen; Ronald F Wolf
Journal:  HPB (Oxford)       Date:  2015-12-21       Impact factor: 3.647

8.  Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.

Authors:  Michelle D Reid; Christina R Stallworth; Melinda M Lewis; Gizem Akkas; Bahar Memis; Olca Basturk; Volkan Adsay
Journal:  Cancer Cytopathol       Date:  2015-09-28       Impact factor: 5.284

Review 9.  Clinicopathological features and surgical outcomes of intraductal tubulopapillary neoplasm of the pancreas: a systematic review.

Authors:  Keiichi Date; Takehiro Okabayashi; Yasuo Shima; Jun Iwata; Tatsuaki Sumiyoshi; Akihito Kozuki; Sojiro Morita; Yasuhiro Hata; Yoshihiro Noda; Akihito Nishioka; Manabu Matsumoto
Journal:  Langenbecks Arch Surg       Date:  2016-03-21       Impact factor: 3.445

10.  Prognostic significance of E-cadherin and ZEB1 expression in intraductal papillary mucinous neoplasm.

Authors:  Ye Rim Chang; Taesung Park; Sung Hyo Park; Yong Kang Kim; Kyoung Bun Lee; Sun-Whe Kim; Jin-Young Jang
Journal:  Oncotarget       Date:  2017-12-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.